Product Name: Recombinant Human F13A (C-6His)

Catalog #: PHH0612



Summary

Name Coagulation Factor XIII A Chain/F13a

Purity Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level <1 EU/μg as determined by LAL test.

Construction Recombinant Human Coagulation Factor XIII A Chain is produced by our

Mammalian expression system and the target gene encoding Gly39-Met732

is expressed with a 6His tag at the C-terminus.

Accession # AAH27963.1

Host Human Cells

Species Human

Predicted Molecular Mass 80.3 KDa

Formulation Supplied as a 0.2 µm filtered solution of 20 mM Tris-HCl, 5% Sucrose, 10%

Glycerol, 0.02% Tween 80, pH8.0.

Shipping The product is shipped on dry ice/polar packs. Upon receipt, store it immediately

at the temperature listed below.

Stability&Storage Store at \leq -70°C, stable for 6 months after receipt. Store at \leq -70°C, stable for 3

months under sterile conditions after opening. Please minimize freeze-thaw

cycles.

Reconstitution


SDS-PAGE image

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838

Product Name: Recombinant Human F13A (C-6His)

Catalog #: PHH0612





Alternative Names

Coagulation Factor XIII A Chain; Coagulation Factor XIIIa; Protein-Glutamine Gamma-Glutamyltransferase A Chain; Transglutaminase A Chain; F13A1; F13A

Background

Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is composed of just 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.

Note

For Research Use Only, Not for Diagnostic Use.